<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758381</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001781-32</org_study_id>
    <nct_id>NCT00758381</nct_id>
  </id_info>
  <brief_title>Metastatic Advanced Pancreas Sorafenib</brief_title>
  <acronym>MAPS</acronym>
  <official_title>A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicentre, open-label, randomized, phase II trial in patients with locally advanced
      or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive
      gemcitabine/cisplatin in combination with Sorafenib (arm A) or gemcitabine/cisplatin alone
      (arm B), as first-line chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to date no standard treatment is available for pancreatic cancer. Although gemcitabine is
      commonly used in patients with pancreatic cancer with the purpose of symptom palliation,
      there is no clear evidence of efficacy in terms of survival increase or progression control.
      Furthermore, attempts at improving results by combining gemcitabine with other cytotoxic
      drugs failed to obtain any advantage. Recently, an EGFR inhibitor (erlotinib) showed a small
      survival advantage when combined with gemcitabine. results obtained with a combination of
      gemcitabine and oxaliplatin seem more promising. A meta-analysis of randomised trials
      comparing gemcitabine versus gemcitabine and platinum analogues showed a statistical
      significant survival advantage for the combination.

      Sorafenib is an inhibitor of the RAS/RAF signalling pathway. Furthermore, sorafenib is able
      to inhibit both VEGFR and PDGFR.

      Since RAS and RAF mutations are quite common in pancreatic cancer, Sorafenib could be useful
      in the management of these tumours. Furthermore, it may be combined with gemcitabine and
      cisplatin without any pharmacokinetic interaction or enhanced toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>time from randomization date to date of local or regional relapse</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- overall Response Rate (RECIST Criteria) - duration of response - overall survival time</measure>
    <time_frame>time from the day of randomization to the date of death from any cause</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg po bid, continuously
Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 400 mg po bid, continuously</intervention_name>
    <description>NEXAVAR*112CPR RIV 200MG
Titolare AIC:
BAYER SpA
Numero di AIC dell'IMP:
037154010</description>
    <arm_group_label>A</arm_group_label>
    <other_name>L01XE05 V</other_name>
    <other_name>Sostanza attiva o descrizione del livello ATC selezionato</other_name>
    <other_name>SORAFENIB TOSILATO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabina, Cisplatino</intervention_name>
    <description>Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>GEMZAR*INFUS 1FL 1G POLV</other_name>
    <other_name>Titolare AIC:</other_name>
    <other_name>ELI LILLY ITALIA SpA</other_name>
    <other_name>Numero di AIC dell'IMP:</other_name>
    <other_name>029452012</other_name>
    <other_name>CISPLATINO TEVA*EV 50MG 100ML</other_name>
    <other_name>TEVA PHARMA ITALIA Srl</other_name>
    <other_name>026543025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent prior to beginning protocol specific procedures

          -  Male or female 18 to 75 years of age

          -  Diagnosis of histologically confirmed adenocarcinoma of the pancreas

          -  Locally advanced (non-resectable) or metastatic pancreatic cancer

          -  Presence of at least one uni-dimensional indicator lesion measurable by CT scan or MRI
             in not an irradiated area (RECIST criteria)

          -  Karnofsky performance status of ≥ 70 at study entry

          -  Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL

          -  Bilirubin level either normal or &lt; 1.5 x ULN

          -  ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present)

          -  Serum creatinine &lt; 1.5 x ULN

          -  Amylase and lipase ≤ 1.5 x the upper limit of normal

          -  PT or INR and PTT &lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation
             treatment with an agent such as warfarin or heparin will be allowed to participate
             provided that no evidence of underlying abnormality in these parameters exists).

          -  Effective contraception for both male and female patients if the risk of conception
             exists

        Exclusion Criteria:

          -  Brain metastases

          -  Previous chemotherapy for locally advanced or metastatic pancreatic cancer.

          -  Adjuvant therapy if documented recurrence is within 6 months after the end of adjuvant
             treatment)

          -  Radiotherapy within 4 weeks prior to study entry

          -  Major surgery within 4 weeks of first dose of study drug

          -  Concurrent chronic systemic immune therapy

          -  Any investigational agent(s) 4 weeks prior to entry

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 6 months

          -  Thrombotic or embolic events such as cerebrovascular accident including transient
             ischemic attacks within the past 6 months

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment

          -  Known drug abuse/ alcohol abuse

          -  Legal incapacity or limited legal capacity

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent

          -  Women who are pregnant or breastfeeding

          -  Acute or subacute intestinal occlusion

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Patients with a previous malignancy but without evidence of disease for ≥
             5 years will be allowed to enter the trial).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Cascinu, M.Professor</last_name>
    <role>Study Chair</role>
    <affiliation>GISCAD Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Cascinu, MProfessor</last_name>
    <phone>+39 071 5964</phone>
    <phone_ext>171</phone_ext>
    <email>cascinu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Rota, Data Manager</last_name>
    <phone>+39 0331 490052</phone>
    <email>centrotrialgiscad@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio, P.le Ospedale n1</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>sandro Barni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Orsola Fatebenefratelli</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale S.Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. san Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Foa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Igea</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gianfranco Pancera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Carlo Borromeo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donata Tabiadon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S.Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Bidoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti Umberto I</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Cascinu, M.Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti, Largo Barozzi, 1</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Labianca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Careggi-Università, Viale Pieraccini, 17</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Di Costanzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Carlo Poma - Via Albertoni, 1</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrico Aitini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Cà Granda, Piazza Ospedale Maggiore, 3</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salvatore Siena, MPr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università Campus Biomedico, Via Emilio Longoni, 83</name>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. S.Giovanni Calabita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Stefano CASCINU, Medical Professor</name_title>
    <organization>Fondazione GISCAD</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>advanced or metastatic</keyword>
  <keyword>sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

